<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002329</url>
  </required_header>
  <id_info>
    <org_study_id>221A</org_study_id>
    <secondary_id>NDPR0002</secondary_id>
    <nct_id>NCT00002329</nct_id>
  </id_info>
  <brief_title>A Study of MDL 28,574A in HIV-Infected Patients</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Oral Dose-Tolerance Study of Oral MDL 28,574A Solution in HIV-Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoechst Marion Roussel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To characterize the safety profile of MDL 28574A following both acute and subchronic dosing&#xD;
      in HIV-positive patients. To determine the MTD of both acute and subchronic doses of this&#xD;
      drug when administered as oral solution. To determine the pharmacokinetic profile of MDL&#xD;
      28574A and castanospermine (from which MDL 28574A is derived) following both acute and&#xD;
      subchronic dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A of the study, patients receive a single oral dose of MDL 28574A on day 1 and are&#xD;
      followed through day 7. In Part B, patients receive single daily doses of the drug on days 1&#xD;
      through 14 and are followed through day 21.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celgosivir hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  CD4 count &gt;= 500 cells/mm3.&#xD;
&#xD;
          -  No evidence of AIDS.&#xD;
&#xD;
          -  No antiretroviral therapy within 30 days prior to study entry.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Presence of lymphadenopathy in two or more extrainguinal sites, at least 1 cm in&#xD;
             diameter for 3 or more months, is permitted.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Clinically significant abnormalities on routine hematology (other than CD4 count and&#xD;
             Western blot), serum chemistry, and urinalysis.&#xD;
&#xD;
          -  Abnormal EKG.&#xD;
&#xD;
          -  Positive stool guaiac.&#xD;
&#xD;
          -  Abnormal medical history or physical exam including temperature, heart rate, and blood&#xD;
             pressure.&#xD;
&#xD;
          -  Clinically significant organ abnormality or disease.&#xD;
&#xD;
          -  Positive urine drug screen for illicit drugs.&#xD;
&#xD;
          -  Inability to comply with study procedures.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Routine treatment with nonprescription medications.&#xD;
&#xD;
          -  Treatment with other medications except with approval of the investigator.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Prior participation in this trial.&#xD;
&#xD;
          -  Serious physical or mental illness within 1 year prior to study entry that would&#xD;
             confound interpretation of data.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral therapy within 30 days prior to study entry.&#xD;
&#xD;
          -  Known medications that alter renal, hepatic, or hematologic/immunologic function (such&#xD;
             as barbiturates, phenothiazines, cimetidine, and immunomodulators) within 14 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Routine treatment with nonprescription medications within 3 days prior to study entry.&#xD;
&#xD;
        History of alcohol or drug abuse within the past year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint Francis Mem Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>MDL 28574</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

